Pharmacokinetics of two pharmaceutical presentations of benznidazole in adult Trypanosoma cruzi infected population.

Background: Benznidazole (BNZ) is the primary treatment for Chagas disease. While pharmacokinetic studies of BNZ began in the 1970s, its metabolism and excretion are not fully understood. Alternatives like Benznidazol Lafepe® and Abarax® have replaced the original Radanil®.